- Home
- REPL
REPL
Replimune Group Inc.
as 07-08-2024 3:35pm EST
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WOBURN |
| Market Cap: | 320.6M | IPO Year: | 2018 |
| Target Price: | $28.67 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.92 - $22.21 | Next Earning Date: | 08-01-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 175.17% |
Stock Insider Trading Activity of Replimune Group Inc. (REPL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Xynos Konstantinos | REPL | Chief Medical Officer | Jun 7 '24 | Sell | $7.50 | 15,881 | $119,107.50 | 117,131 | SEC Form 4 |
| Love Colin | REPL | Chief Operating Officer | May 16 '24 | Sell | $6.47 | 17,615 | $113,969.05 | 777,345 | SEC Form 4 |
| Astley-Sparke Philip | REPL | Executive Chairman | May 16 '24 | Sell | $6.47 | 37,928 | $245,394.16 | 1,487,350 | SEC Form 4 |
| Coffin Robert | REPL | Director | May 16 '24 | Sell | $6.47 | 11,464 | $74,172.08 | 1,821,872 | SEC Form 4 |
| Schwendenman Andrew | REPL | Chief Accounting Officer | May 16 '24 | Sell | $6.47 | 2,298 | $14,868.06 | 38,238 | SEC Form 4 |
| Patel Sushil | REPL | Chief Executive Officer | May 16 '24 | Sell | $6.47 | 20,194 | $130,655.18 | 212,014 | SEC Form 4 |
| Xynos Konstantinos | REPL | Chief Medical Officer | May 16 '24 | Sell | $6.47 | 6,367 | $41,194.49 | 133,012 | SEC Form 4 |
| Sarchi Christopher | REPL | Chief Commercial Officer | May 16 '24 | Sell | $6.47 | 2,218 | $14,350.46 | 92,252 | SEC Form 4 |
| Xynos Konstantinos | REPL | Chief Medical Officer | Nov 16 '23 | Sell | $10.92 | 7,313 | $79,857.96 | 112,714 | SEC Form 4 |
Latest Replimune Group Inc. News
REPL Breaking Stock News: Dive into REPL Ticker-Specific Updates for Smart Investing
MT Newswires
25 days ago
Replimune Group Signs $100 Million PIPE Deal with Institutional Investors
GlobeNewswire
25 days ago
Replimune Announces $100 Million Private Placement Financing
PR Newswire
a month ago
See's Candies® Launches New Scotchmallow® Littles
Yahoo Finance Video
a month ago
Stock futures slip as markets digest hot jobs data
PR Newswire
a month ago
SOUTHWEST AIRLINES RANKED TOP AIRLINE ON FORBES AMERICA'S BEST EMPLOYERS FOR VETERANS LIST
PR Newswire
a month ago
IBHS honors resilient construction trailblazers
Investor's Business Daily
a month ago
Lyft Stock Rides High On Bullish Double-Upgrade After Company Offers New Growth Targets
Benzinga
a month ago
Bill Gates Could Be The World's First Trillionaire If He Had 'Diamond Handed' His Microsoft Shares — He'd Be Sitting On $1.47 Trillion Today
Share on Social Networks:
Disclaimer
The information presented on this page, "REPL Replimune Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.